• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

    14.39 +3.10 (+27.46%)
    Streaming Delayed Price Updated: 1:12 PM EST, Jan 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 21,135,580
    Open 16.19
    Bid (Size) 14.38 (600)
    Ask (Size) 14.40 (1,000)
    Prev. Close 11.29
    Today's Range 13.71 - 16.39
    52wk Range 5.950 - 62.75
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗
    The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder. 
    Via Stocktwits

    Performance

    YTD
    +20.4%
    +20.4%
    1 Month
    -4.5%
    -4.5%
    3 Month
    +58.1%
    +58.1%
    6 Month
    -70.2%
    -70.2%
    1 Year
    -71.3%
    -71.3%

    More News

    Read More
    Get insights into the top gainers and losers of Thursday's pre-market session. ↗
    Via Chartmill
    News headline image
    MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
    From DJS Law Group
    Via Business Wire
    News headline image
    MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces That MoonLake Immunotherapeutics Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
    Via TheNewswire.com
    Topics Lawsuit
    News headline image
    MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces That MoonLake Immunotherapeutics Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    MLTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action – MLTX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    MOONLAKE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    MLTX Investor Deadline Alert: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms
    From Hagens Berman
    Via Business Wire
    News headline image
    DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025
    From Berger Montague
    Via GlobeNewswire
    News headline image
    MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics (NASDAQ: MLTX)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics (NASDAQ: MLTX)
    From Bernstein Liebhard LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is MoonLake Immunotherapeutics - Class A Ordinary Shares publicly traded?
    Yes, MoonLake Immunotherapeutics - Class A Ordinary Shares is publicly traded.
    What exchange does MoonLake Immunotherapeutics - Class A Ordinary Shares trade on?
    MoonLake Immunotherapeutics - Class A Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares?
    The ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares is MLTX on the Nasdaq Stock Market
    What is the current price of MoonLake Immunotherapeutics - Class A Ordinary Shares?
    The current price of MoonLake Immunotherapeutics - Class A Ordinary Shares is 14.39
    When was MoonLake Immunotherapeutics - Class A Ordinary Shares last traded?
    The last trade of MoonLake Immunotherapeutics - Class A Ordinary Shares was at 01/08/26 01:12 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.